31 filings
8-K
VTYX
Ventyx Biosciences Inc
5 Apr 24
Departure of Directors or Certain Officers
5:05pm
8-K
VTYX
Ventyx Biosciences Inc
11 Mar 24
Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides
9:01am
8-K
VTYX
Ventyx Biosciences Inc
7 Mar 24
Ventyx Biosciences Announces $100 Million Private Placement of Common Stock
8:45am
8-K
VTYX
Ventyx Biosciences Inc
27 Feb 24
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
4:08pm
8-K
VTYX
Ventyx Biosciences Inc
7 Dec 23
Cost Associated with Exit or Disposal Activities
4:30pm
8-K
4ggwpbjsgqg252
22 Nov 23
Departure of Directors or Certain Officers
4:57pm
8-K
tkt 5b288yydsget1
9 Nov 23
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
4:05pm
8-K
4uscxk5mcxc53fw6w
6 Nov 23
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16
5:15pm
8-K
kltto77wyus2bo85
10 Oct 23
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-to-Severely Active Ulcerative Colitis
6:17am
8-K
xsyz h7jaw
10 Aug 23
Ventyx Biosciences Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Progress
4:07pm
8-K
fix4 cbz0ywzh
25 Jul 23
Entry into a Material Definitive Agreement
6:58pm
8-K
kbxq2wt
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
ciq1hc
11 May 23
Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
4:07pm
8-K
3nyhuu7re6npxks
23 Mar 23
Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
4:05pm
8-K
q2yrlp
26 Jan 23
Regulation FD Disclosure
4:07pm
8-K
t5yq3v2i4e2eu
12 Jan 23
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors
4:05pm
8-K
mawba6 wkal6qc
20 Dec 22
Entry into a Material Definitive Agreement
4:54pm
8-K
sc5y7vc5dpc q5
12 Dec 22
Amendments to Articles of Incorporation or Bylaws
5:00pm
8-K
q7jic zpny
30 Nov 22
Regulation FD Disclosure
4:37pm
8-K
5zlo6jfix 9annk
3 Nov 22
Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
4:10pm